Physician profile
Bernard Drexinger
NPI 1407849888
$5,492.59
in general payments reported to CMS, 2019-2025
60 companies · $1,698 in 2025
The $1,698 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $607 · 2020: $414 · 2021: $762 · 2022: $626 · 2023: $600 · 2024: $786 · 2025: $1,698.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,784 · Consulting Fee: $200 · Education: $100.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,784.08 |
| Consulting Fee | $200.00 |
| Education | $100.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $658.91 | 2021-2025 | Qulipta |
| Pfizer INC. | $428.09 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $317.42 | 2019-2025 | Austedo Xr, Austedo Xr, Ajovy |
| Mdd US Operations, LLC | $277.60 | 2019-2025 | Gocovri, Gocovri, Qelbree |
| Amneal Pharmaceuticals LLC | $252.03 | 2019-2025 | Rytary, Crexont |
| Harmony Biosciences LLC | $235.51 | 2021-2025 | Wakix |
| Ucb, INC. | $232.15 | 2019-2025 | Nayzilam, Briviact |
| Avadel Cns Pharmaceuticals, LLC | $200.00 | 2025 | Lumryz |
| Csl Behring | $195.63 | 2021-2025 | Hizentra |
| Biogen, INC. | $176.71 | 2021-2025 | Tysabri, Vumerity, Leqembi |
| Lundbeck LLC | $143.79 | 2022-2025 | Vyepti |
| Lilly USA, LLC | $135.73 | 2019-2025 | Kisunla |
| Argenx US, INC. | $132.03 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Avanir Pharmaceuticals, INC. | $120.52 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $117.27 | 2022-2025 | Hyqvia, Gammagard |
Show all 60 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bernard Drexinger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.